頭頚部癌における照射とシゾフィランの併用

概要

論文の詳細を見る
The effect of the concurrent use of Sizofiran (SPG) and radiation therapy for head and neck cancers was evaluated by tests of cell-mediated immunity in the peripheral blood of patients. The administration of SPG was started at the beginning of radiation therapy. It was administered intramuscularly in a dose of 40 mg once a week during hospitalization and 40 mg once every 2 weeks during outpatient care. This regimen was continued for 1 yearafter the completion of basic treatment. The subjects were 39 patients with stage III or stage N head and neck cancers treated at the Department of Otolaryngology, Teikyo University Hospital between May, 1988 and April, 1991. Twenty-four of these patients received SPG plus radiotherapy (SPG group), and the remaining 15, who received only radiotherapy, were considered to be controls. The subjects were allotted to the two groups by the envelope method. 1) Cell-mediated immunity was reduced by irradiation. 2) The reduction in cell-mediated immunity after irradiation was milder in the SPG group than in the control group. 3) The recovery of cell-mediated immunity was greater in the SPG group than in the control group 1 month after the completion of the basic treatment. These findings indicate that SPG prevents the suppression of cell-mediated immunity and promotes its recovery during radiation therapy for head and neck cancer.
耳鼻咽喉科臨床学会の論文